Pipeline

We are building a deep pipeline of potentially differentiated therapies, with the goal of advancing care and outcomes for patients with diverse inflammatory diseases

  • Preclinical
  • Phase I
  • Phase II
  • Phase III

CBP-201

Antibody targeting IL-4Rα cytokine receptor
(Th2 cell modulator)

  • Preclin
  • Ph 1
  • Ph 2
  • Ph 3
Atopic Dermatitis (AD)
  •  
  •  
  •  
  •  
  •  
Atopic Dermatitis (AD)
Asthma*
  •  
  •  
  •  
  •  
  •  
Asthma*
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)*
  •  
  •  
  •  
  •  
  •  
Chronic Rhinosinusitis with
Nasal Polyps (CRSwNP)*

CBP-307

Small molecule targeting S1P1
(Th1 cell modulator)

  • Preclin
  • Ph 1
  • Ph 2
  • Ph 3
Ulcerative Colitis (UC)
  •  
  •  
  •  
  •  
  •  
Ulcerative Colitis (UC)
Crohn's Disease (CD)**
  •  
  •  
  •  
  •  
  •  
Crohn's Disease (CD)**

CBP-174

Peripherally restricted
H3 receptor antagonist

  • Preclin
  • Ph 1
  • Ph 2
  • Ph 3
Pruritus Associated with AD***
  •  
  •  
  •  
  •  
  •  
Pruritus Assoc.
with AD***

CBP-233

Antibody targeting IL-33

  • Preclin
  • Ph 1
  • Ph 2
  • Ph 3
Allergic Inflammation
  •  
  •  
  •  
  •  
  •  
Allergic
Inflammation

* Advancing into Phase 2. We plan to initiate a Phase 2 clinical trial in these indications (asthma and CRSwNP) based on PK results from our completed Phase 1a study in healthy volunteers.
**  Phase 2 Study ended early due to COVID-19-related enrollment challenges. New Phase 2 trial planned.
***  Advancing into Phase 1.

  • Key:
  • Ongoing
  • Planned
Don't delete this section - it contains the styling for the pipeline bars, but is invisible to visitors